The FDA’s Office of Prescription Drug Promotion (OPDP) issued an Untitled Letter, backdated to September 23, to Tracey M. Henderson, MS, MBA – AstraZeneca’s promotional regulatory affairs review ...
Phase 3 ARENSENS clinical trial results were presented at JADPRO 2025, indicating darolutamide plus ADT improved rPFS in prostate cancer.
一些您可能无法访问的结果已被隐去。
显示无法访问的结果
反馈